Naltrexone for extended-release injectable suspension + Oral naltrexone
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Opioid-Related Disorders
Conditions
Opioid-Related Disorders
Trial Timeline
Sep 21, 2017 → Jun 30, 2019
NCT ID
NCT02978417About Naltrexone for extended-release injectable suspension + Oral naltrexone
Naltrexone for extended-release injectable suspension + Oral naltrexone is a approved stage product being developed by Alkermes for Opioid-Related Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT02978417. Target conditions include Opioid-Related Disorders.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02978417 | Approved | Completed |
Competing Products
2 competing products in Opioid-Related Disorders
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Naltrexone | Alkermes | Approved | 82 |
| Slow release oral morphine (SROM) + Methadone | Mayne Pharma Group | Phase 3 | 69 |